Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Summary Marketline's Acorda Therapeutics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Acorda Therapeutics, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown ...
Vectura Group plc: 2019 Preliminary Results 2019 Preliminary Results - Vectura reports 2019 financial performance ahead of expectations, with strong operational delivery - - Executing the strategy to become an industry-leading specialist inhalation CDMO - Chippenham, UK – 17 March 2020: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") today announces its preliminary results for the year ended 31 December 2019. Financial highlights 20192018% changeRevenue£178.3m£160.5m11.1%Gross profit£95.3m£98.9m(3.6%)R&D(£50.2m)(£55.5m)(9.5%)Adjusted EBITDA1£43.4m£39.0m11.3%Operating lo...
Vectura Group appoints New Chief Executive Officer Vectura Group appoints New Chief Executive Officer Will Downie joins from Catalent Inc., one of the world’s largest Contract Development and Manufacturing Organisations Chippenham, UK – 29 October 2019: Vectura Group plc (LSE: VEC) ("Vectura", the "Group", or the "Company"), is pleased to announce the appointment of Will Downie as CEO and Executive Director of the Company with effect from 7th November 2019. Prior to joining Vectura, Will spent ten years as the Senior Vice President, Global Sales and Marketing at Catalent Inc., one of t...
Vectura provides update on GSK Litigation Vectura provides update on GSK Litigation Chippenham, UK – 13 September 2019: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") announces that following the award of US$89.7m in damages to Vectura by a jury in the US District Court for the District of Delaware on 3 May 2019, presiding US District Judge Richard Andrews has ruled on the parties’ post-trial motions: Award of US$89.7m in damages to Vectura on May 3, 2019 upheldOngoing royalties of 3% on US sales of certain infringing GSK Ellipta productsSupplemental damages based on GSK’s infrin...
Vectura delivers strong financial performance for H1 2019 and confirms proposed special dividend of approximately £40m in aggregate plus a £20m buyback programme Vectura delivers strong financial performance for H1 2019 and confirms proposed special dividend of approximately £40m in aggregate plus a £20m buyback programme Chippenham, UK – 10 September 2019: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") announces its unaudited Interim Results for the six months ended 30 June 2019. Financial highlights H1 2019H1 2018% change Revenue£91.7m£79.9m14.8%Gross profit£51.9m£52.6m(1.3%)...
Vectura Group plc: Proposed Special Dividend and Share Consolidation, Share Buyback Programme and Dividend Reinvestment Plan Vectura Group plc ("Vectura" or the "Company") Proposed Special Dividend and Share Consolidation, Share Buyback Programme and Dividend Reinvestment Plan Chippenham, UK – 10 September 2019: Vectura Group plc (LSE:VEC) (“Vectura” or “the Company”) today announces a proposed Special Dividend and Share Consolidation, Share Buyback Programme and Dividend Reinvestment Plan. On 17 July 2019, the Board announced its intention to undertake a capital return of approximately ...
The general evaluation of VECTURA GROUP PLC. (GB), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date August 16, 2019, the closing price was GBp 78.70 an...
Vectura confirms R&D investment priorities, announces a proposed £50 million capital return and a pre-close trading update This announcement contains inside information Vectura confirms R&D investment priorities, announces a proposed £50 million capital return and a pre-close trading update Chippenham, UK – 17 July 2019: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") today confirms its R&D investment priorities, announces a proposed £50 million capital return and provides an unaudited pre-close trading update. Paul Fry, Interim Chief Executive Officer of Vectura, commented: “V...
CHIPPENHAM, United Kingdom--(BUSINESS WIRE)-- Vectura Group plc (LSE:VEC) ("Vectura" or "the Group") confirms that on 3rd May 2019 following a jury trial in the United States District Court for the District of Delaware, the relevant asserted claim of Vectura’s US patent 8303991 was found valid and infringed by US sales of three of GlaxoSmithKline’s (GSK) Ellipta products. The jury awarded Vectura $89.7m in damages for the period from August 2016 through December 2018, based on a calculation of 3% of US sales of these products. Vectura ...
Vectura Group plc 2018 Preliminary Results This contains inside information 2018 Preliminary Results - Vectura reports strong 2018 financial and operational performance - Chippenham, UK – 26 March 2019: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") today announces its preliminary results for the year ended 31 December 2018. Financial highlights 20182017% changeRevenue£160.5m£148.0m8.4%Gross profit£98.9m£90.8m8.9%R&D(£55.5m)(£60.3m)8.0%Adjusted EBITDA1£39.0m£25.8m51.2%Operating loss(£105.4m)(£96.2m)(9.6%)Basic loss per share(1...
Building on its positive adjusted H118 EBITDA and its partnerships, Vectura has announced three recent additional developments. Partner Mundipharma received a positive EU opinion for flutiform (46% of H118 revenues) for the treatment of asthma in children, expanding its market from adults and adolescents. The agreement with Hikma to develop generic versions of GSK’s Ellipta brings upfront and milestone payments and ensures Vectura’s participation in the global respiratory disease market irre...
Vectura Group plc (VEC:GBR) currently trades well below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 5.1x Uniform P/E, implying very bearish expectations for the firm, and management has concerns about Sular sales declines, respiratory field performance, and the potential of their pipeline Specifically, management may have concerns about their ability to drive more high-value revenues from Sular, and to sustain current in-market performance. Additionally, they may lack ...
Vectura Group announces global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio Vectura Group announces global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio Upfront payment of US$15mUp to US$80m of development milestone payments Mid teen percentage profit share arrangement for each portfolio product Chippenham, UK – 08 November 2018: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), today announces signing an agreement with Hikma Pharmaceuticals PLC ("Hikma") for the global development and commercialisation of generic vers...
Vectura Group plc: Interim Results This contains inside information Vectura Group plc Vectura regaining momentum with continued inhaled revenue and adjusted EBITDA growth Chippenham, UK - 11 September 2018: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") announces its unaudited Interim Results for the six months ended 30 June 2018 and reiterates its current guidance for the full year. Financial & Operational Highlights H1 2018£mH1 2017£m % changeRevenue1 79.9 78.8 1.4% Inhaled64.7 60.4 7.1% Other (non-inhaled)15.2 18.4 (17.4%)Gross profit52.6 50.4 4.4%R&D expenditure(25.3)(...
A director at Vectura Group maiden bought 49,033 shares at 74p and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.